Compare IDEXX Laboratories, Inc. (IDXX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Visa Inc — how do they compare? IDEXX Laboratories, Inc. trades at $552.09 (market cap $44.48B), while Visa Inc trades at $358.77 (market cap $685.71B). The key difference: Visa Inc is far larger — about 15.4× IDEXX Laboratories, Inc.'s market cap, and Visa Inc pays a 0.74% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | V | |
|---|---|---|
Market Cap | $44.48B | $685.71B |
Sector | Health | Financials |
52-Week High | $766.68 | $365.14 |
52-Week Low | $520.87 | $295.52 |
Enterprise Value | $45.38B | $696.30B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Visa (V) trades at $358.33, down slightly by 0.06% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $396.70. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding expectations, and maintains robust profitability with a net income margin of 51.68%. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for growth in digital payments.
The stock offers upside potential driven by earnings momentum and strategic initiatives in AI and digital payments, but faces risks from competitive fintech disruption and regulatory scrutiny. Institutional ownership trends show continued interest, with 85% of analysts rating it a buy. Investors should monitor the Q2 2026 earnings report on April 28, 2026, for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
